On Monday, Speed Commerce Inc (NASDAQ:SPDC)’s shares declined -11.69% to $0.309.
Speed Commerce Inc (SPDC) declared that it has closed the recently declared registered direct placement of 13,035,713 shares of its common stock, and warrants to purchase up to 9,776,784 shares of its common stock, at a combined public offering price of $0.56 per share and related warrants for total gross proceeds of $7.3 million.
Roth Capital Partners acted as the exclusive placement agent for the transaction.
provides e-commerce and fulfillment services to retailers and manufacturers in the United States and Canada. It offers Web platform development and hosting, order administration, fulfillment, logistics, and contact center services, which provide customers with transaction-based services and information administration tools.
Syngenta AG (ADR) (NYSE:SYT)’s shares dropped -7.65% to $71.95.
Syngenta AG (ADR) (SYT) declared that the 2014 annual report for Syngenta Finance NV has been filed with the Luxembourg Stock Exchange and the Netherlands Authority for the Financial Markets (AFM).
The document is accessible on the Syngenta corporate website here.
Hard copies of the financial statements are accessible free of charge upon request.
Syngenta AG, an agribusiness company, engages in the discovery, development, manufacture, and marketing of a range of products designed to enhance crop yields and food quality worldwide.
At the end of Monday’s trade, Capstone Turbine Corporation (NASDAQ:CPST)‘s shares dipped -0.587% to $5.17.
Capstone Turbine Corporation (CPST) declared that it received an order for a C800 microturbine to upgrade a leading pork producer in Lithuania.
Sarlin Oy Ab, Capstone’s distributor for Finland, Latvia, Estonia and Lithuania, secured the order, which is predictable to be commissioned in October 2015.
Capstone Turbine Corporation develops, manufactures, markets, and services microturbine technology solutions for use in stationary distributed power generation applications worldwide.
Spark Therapeutics Inc (NASDAQ:ONCE), ended its Monday’s trading session with -6.00% loss, and closed at $55.01.
Spark Therapeutics Inc (ONCE) declared that it will have several presentations during the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), taking place in Denver, Colorado, from May 3rd through May 7th in addition to at the Retina Gene Therapy conference in Denver on May 8th. ARVO is the largest gathering of eye and vision researchers in the world, attracting over 11,000 attendees from more than 75 countries.
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company is developing SPK-RPE65, which is in Phase III clinical trial for the treatment of inherited retinal dystrophies, a group of rare blinding conditions caused by non-sex linked, or autosomal recessive, mutations in the RPE65 gene.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
